Kornimate/medical-research-clean huggingface dataset:
personal fet in rif patients according to histological dating of endometrial of natural/ hormone replacement cycle

Conditions: Infertility, Female

Summary: at present, the evaluation criterion of endometrial receptivity is controversial. the development of a molecular diagnostic tool, the endometrial receptivity array (era) for diagnosis of endometrial receptivity . but use of this test in patients with rif has shown that the window of implantation (woi) is displaced in only a quarter of these patients and use of a personalized embryo transfer (pet) on the day designated by era improves reproductive performance with higher cost .what is known to the others'population? the morphological changes observed on histology for each specific day after ovulation were described by noyes and his colleagues in 1950 . an endometrial biopsy that shows a difference of more than 2 days between the histologic dating and actual day after ovulation is considered to be ''out of phase''. but such pet studies according to the noyes criterion are lacking . the aim of this study is to explore the personal frozen-thawed embryo transfer in unexplained rif patients according to the blinded histological dating of endometrial biopsies .


Eligibility criteria:
inclusion criteria: the inclusion criteria for rif group were: •unexplained repeated implantation failure (rif) which is defined as the absence of a gestational sac on ultrasound at 5 or more weeks after embryo transfer (et) after 3 embryo transfers with high quality embryos or after the transfer of ≥10 embryos in multiple transfers. the inclusion criteria for control group were: * age \<35 years; * regular menstrual cycles of 24-35 days; * baseline follicle- stimulating hormone (fsh) \< 9.0 iu/l; * endometrial thickness ≥8.0 mm on the day of hcg administration. exclusion criteria: * uterine abnormalities (double uterus, bicornuate uterus, unicornuate uterus); * intrauterine adhesions（moderate - severe）, endometriosis, adenomyosis, untreated hydrosalpinx, uterine fibroids (submucosal fibroids, nonmucosal fibroids \>4.0 cm and/or endometrial pressure) * history of adverse pregnancy (including spontaneous abortion, stillbirth, and fetal malformation).
fecal microbiota transplantation for c diff infection

Conditions: Clostridium Difficile Infection

Summary: the objective of this study is to provide treatment with fecal microbiota transplantation (fmt) to patients with recurrent or refractory clostridium difficile infection (cdi). it has been shown that good bacteria (like that found in the stool from a healthy donor) attack clostridium difficile in multiple ways: they make substances that kill clostridium difficile - and they attach to the surface of the colon lining, which prevents the clostridium difficile toxin (poison) from attaching. fmt involves infusing a mixture of saline and stool from a healthy donor into the bowel of the patient with cdi during a colonoscopy. the method used to deliver the fmt will depend on individual characteristics of the subject and is at the discretion of the treating physician. fmt may be administered by the following methods. * colonoscopy: this method allows full endoscopic examination of the colon and exclusion of comorbid conditions (such as ibd, malignancy or microscopic colitis) which may have an impact on subject's treatment or response to therapy. * sigmoidoscopy: this method still allows infusion of the stool into a more proximal segment of the colon than an enema, but may not require sedation. this method may be beneficial in subjects who are elderly or multiparous and who may have difficulty retaining the material when given as enema. sigmoidoscopic administration eliminates the additional risks associated with colonoscopy in subjects who may not have a clear indication for colonoscopy. * retention enema: this method may be preferable in younger subjects who have already had recent endoscopic evaluation, in subjects who prefer not to undergo endoscopy or in subjects with significant co morbidities and may not tolerate endoscopy. the physician will administer 300-500 ml of the fecal suspension in aliquots of 60 ml, through the colonoscope or sigmoidoscope or 150 ml via retention enema. in cases of colonoscopic delivery, the material will be delivered to the most proximal point of insertion. the subject is encouraged to retain stool for as long as possible.


Eligibility criteria:
inclusion criteria: 1. subject is at least 18 years old. 2. subject has recurrent or relapsing cdi defined as: * at least three episodes of mild-to-moderate cdi and failure of a 6-8 week taper with vancomycin with or without an alternative antibiotic (e.g., rifaximin, nitazoxanide, fidaxomicin). or * at least two episodes of severe cdi resulting in hospitalization and associated with significant morbidity. or * moderate cdi not responding to standard therapy (vancomycin) for at least a week. or * severe c. difficile infection with toxic megacolon, not responding to standard therapy or the use of ivig. 3. subject is willing and able to provide informed consent. 4. if a female of childbearing potential, subject has agreed to use an acceptable form of birth control for up to 4 weeks after fmt treatment. exclusion criteria: 1. subject is pregnant. 2. subject is unable to comply with study requirements.

Keywords: c diff cdi clostridium difficile associated diarrhea
ultrasound guided psoas compartment block vs suprainguinal fascia iliaca compartment block

Conditions: Pain, Postoperative; Hip Dysplasia

Summary: the aim of this study was to compare the intraoperative and the postoperative analgesic effect of psoas compartment block (pcb) and supra-inguinal fascia iliaca compartment block (sfib) in pediatric patients undergoing developmental dysplasia of the hip

all subjects after entering operation room will be connected to standard monitor electrocardiograph, non-invasive blood pressure, heart rate, oxygen saturation. three mg/kg of propofol, 0.2 μg/kg of fentanyl and 0.1 mg/kg midazolam will be used for sedation. oxygen at the concentration of 100% will be administrated under the mask in all patients after satisfactory sedation, tracheal intubation will be performed after intravenous anesthesia with administration of 3 mg/kg of propofol, 0.6 μg/kg of fentanyl and 0.9 mg/kg of rocurium. after intubation 2-3% of sevoflurane and 0.2-0.3 mcg/kg/min of fentanyl will be used to maintain anesthesia guided by psi and hemodynamic monitoring. the two groups will receive nerve block with local anesthetics. in the sfib group, the patients will receive ultrasound-guided sfib, while the patients in the pcb group will receive pcb under the guidance of ultrasound. local anesthetic 0.25% ropivacaine will be used at 1 ml/kg for sfib and pcb. (the dose of local anesthetic for sfib or pcb was not more than 35ml). all blocks will be performed by the same experienced anesthesiologist.

Eligibility criteria:
inclusion criteria: * patients undergoing undergo acetabuloplasty * anesthesiologists (asa) physical status of i to ii exclusion criteria: * known allergy to local anesthetic * infection at the block site.
short-course isoniazid and rifampin compared with isoniazid for latent tuberculosis infection

Conditions: Tuberculosis

Summary: the objective of the study was to compare the compliance and the side effects of a short course to treatment of latent tuberculosis infection during 3 months(isoniazid plus rifampin)group i, with the standard course for 6 months(isoniazid)group ii .prospective, comparative, randomized and open trial of patients with positive tst and the suitable criteria for treatment, in accordance with the guidelines of the cdc, excluding hiv infection. 105 patients were included. in conclusion, a short course with isoniazid plus rifampin during 3 months shown better compliance with a lower percentage of abandonment that the course 6h. tolerance is similar in the two courses.

introduction: the objective of the study was to compare the compliance and the side effects of a short course to treatment of latent tuberculosis infection during 3 months with the standard course for 6 months. methods: prospective, comparative, randomized and open trial of patients with positive tst and the suitable criteria for treatment, in accordance with the guidelines of the cdc, excluding hiv infection. the group i was assigned to isoniazid (h) at a dose of 300 mg per day for 6 months and the group ii was assigned to isoniazid at a dose of 300 mg per day plus rifampin (r) (600 mg per day) for 3 months. the patients were followed for five years. results: 105 patients were included, of which 9 refused the treatment; 45 patients were included in the group i and 51 patients in the group ii. both groups were comparable at base level. the hepatotoxicity was 44% in the group 6h and 29% in the group 3hr (p = 0,07). the hepatotoxicity was severe in 6.7% in the group 6h and 5.8% in the group 3hr; these obliged the suspension of treatment in 4.4% and 1.9%, respectively (p =ns). the proportion of patients who completed the study treatment was 75.6% of the patients in the group 6h, and 90.2% in the group 3hr (p = 0,05). only a case of tuberculosis was detected in the second month treatment with 6h. conclusion: in the treatment of latent tuberculosis infection, a short course with isoniazid plus rifampin during 3 months shown better compliance with a lower percentage of abandonment that the course 6h. tolerance is similar in the two courses.

Eligibility criteria:
inclusion criteria: * patients with positive tst and the suitable criteria for treatment, in accordance with the guidelines of the cdc: exclusion criteria: * hiv infection. * hepatopathy * previous treatment of of latent tuberculosis infection. * allergy to drugs.

Keywords: latent tuberculosis infection. isoniazid. rifampin. clinical trial. treatment of latent tuberculosis infection
translational obesity research

Conditions: Obesity

Summary: the proposed project takes an innovative approach to childhood obesity prevention, for which there currently no evidence-based programs, and for which results of current trials have produced mainly short-term or disappointing effects. the aim of this project is to adapt and revise parts of two nationally recognized programs for drug prevention for use with children in grades 4-6 with the express purpose of obesity prevention. the current study will attempt to promote emotion regulation, neuro-cognitive function, and social competence in order to prevent obesity. a total of 24 elementary schools from two of the largest districts in orange county will be randomly assigned to either the obesity prevention program or control group (n=1587) 4th grade students and their parents). a cohort of students will be followed from the 4th through 6th grades. intervention students will be administered the pathways obesity prevention program by trained teachers. the population is ethnically diverse (36% white, 57% hispanic, 6%asian; 48% on free/reduced lunch programs). self-report measures, bmi, and waist circumference will be administered at the beginning of 4th grade, and at end of 4th , 5th , and 6th grade. teacher, administrative, and parent surveys will be administered on the same schedule to measure school environment. program implementation will be measured by teacher self-report and research staff observations. data will be analyzed with statistical approaches that capture effects of school and classroom, test the theoretical model of change, and evaluate developmental trends in mediators and outcomes across the three grades. findings should be generalizable to most elementary schools, and will be used to develop evidence-based program standards for childhood obesity prevention.


Eligibility criteria:
inclusion criteria: * 4th grade students at participating schools exclusion criteria: * none

Keywords: obesity prevention health promotion school based curriculum
effect of rifampin on the pharmacokinetics of dapagliflozin in healthy subjects

Conditions: Type 2 Diabetes Mellitus

Summary: the purpose of the study is to assess the effects of rifampin on the pharmacokinetics of dapagliflozin


Eligibility criteria:
inclusion criteria: * healthy subjects * body mass index (bmi) of 18 to 32 inclusive * women who are not of childbearing potential and men, ages 18 to 45 exclusion criteria: * evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, electrocardiogram (ecg) or clinical laboratory determinations * glucosuria * abnormal liver function tests
the effect of autologous autovaccine in patients with allergy on house-dust-mite

Conditions: Allergens, House Dust Mites

Summary: house dust mite allergy is a common problem, resulting in asthma, chronic swelling of the eyes, and running nose. the investigators test a possibility to immunize subjects sensitized against house dust mite with extracts from their own gut bacteria "auto-vaccination".

see above

Eligibility criteria:
inclusion criteria: * informed consent * age 18-35 years * known allergy on house-dust mite * gina 0-1 exclusion criteria: * anamnestic incompatibility to parts of autovaccine * asthma \> gina i° * chronic disease conditions or infections * pregnancy * inhalative or systemic steroid use * any immunosuppressive therapy * intake of any other probiotic medication (e.g. e.coli nissle 1917) * participation in any other study at the same time * substance abuse * incapability of understanding the study's purpose and performance * smoker

Keywords: house dust mite asthma autovaccine allergy
a study to evaluate the pharmacokinetics of vi-0521 in subjects with hepatic impairment

Conditions: Hepatic Impairment

Summary: this study is designed to determine the effects of a single dose of the study medication in subjects with and without hepatic impairment. 18 to 24 subjects will participate by having multiple blood draws taken to measure the level of study medication in their blood over time.

this study will look at the effect of a single does of study medication in three groups. each group will have 6 - 8 subjects with similar levels of hepatic impairment. group 1 will have normal hepatic function. groups 2 and 3 will be made up of subjects with mild to moderate hepatic impairment. subjects will have blood taken at specific intervals to measure study medication levels. subject participation will last approximately 7 to 9 days.

Eligibility criteria:
inclusion criteria: a total of 18 to 24 subjects will be studied in 3 groups of 6-8 subjects per group. group 1 will consist of 6-8 males or females with normal hepatic function, 18 to 65 years of age inclusive. groups 2-3 will consist of 6-8 males or females per group with varying degree of stable hepatic impairment. exclusion criteria: any subject meeting the following criteria must be excluded from the trial: 1. known history of clinically significant arrhythmias. 2. acute illness, especially any infection, within 2 weeks of dosing. 3. history or presence of: * alcoholism or drug abuse within the past 2 years. * hypersensitivity or idiosyncratic reaction to compounds related to the study drug or related compounds. 4. any history of bipolar disorder or psychosis, history of psychiatric hospitalization, greater than one lifetime episode of major depression. 5. blood donation or significant blood loss within 56 days prior to day 1. 6. plasma donation within 7 days prior to day 1. 7. any subject who has participated in a previous clinical trial with vi-0521. 8. any subject who received an investigational drug within 30 days prior to dosing in this study. 9. any history of glaucoma, increased intraocular pressure, or medications to treat increased intraocular pressure. 10. serum creatinine \> 1.5 for male subjects, and \>1.4 for female subjects. 11. history of kidney stones in the last 6 months 12. female subjects, who may be pregnant, or are lactating. 13. use of any drug that is known to have clinical significance in inhibiting or inducing liver enzymes involved in drug metabolism. 14. use of tobacco or nicotine products within last 6 months unless subject is hepatically-impaired.

Keywords: pharmacokinetics
can hypermobility of first ray affect surgical treatment of hallux valgus

Conditions: Hallux Valgus

Summary: hallux valgus can be associated with hypermobility of 1st ray. surgical decision for hallux valgus can be affected by hyper mobility of 1st ray so our clinical trial involved patients with bilateral hallux valgus were planned to underwent fusion of 1st ray and soft tissue correction plus bonionectomy for one foot and for other foot surgical treatment involves corrective osteotomy and soft tissue procedure plus bonionectomy without fusion of 1st tarsometatarsal joint.


Eligibility criteria:
inclusion criteria: * hallux valgus with 1st ray hypermobility exclusion criteria: 1. generalized ligament laxity 2. previous foot and ankle surgery 3. diabetes mellitus

Keywords: hallux valgus first ray hypermobility fusion corrective osteotomy functional outcome
intra-nasal ketamine for analgesia in the emergency department

Conditions: Pain

Summary: the provision of analgesia to patients in pain is a fundamental necessity of emergency department practice and is usually accomplished using iv opioids. however, significant barriers exist to the provision of timely analgesia by the iv route. the use of the in route for medication delivery provides an efficient and relatively painless mode of analgesia delivery. as well, ketamine is well-known to be an effective analgesic and to preserve cardiorespiratory function thus removing the necessity of physiologic monitoring that is obligatory when using opioids. the use of ketamine by the in route provides a rapid, easy-administered and well-tolerated method for providing analgesia in the ed setting.


Eligibility criteria:
inclusion criteria: * age 6 years or greater * moderate or severe pain (vas \>=50mm) exclusion criteria: * history of allergy or intolerance to ketamine * structural or functional nasal occlusion * inability to understand the vas * glasgow coma scale \< 15 * systolic bp \> 180 * history of schizophrenia * clinical necessity for immediate iv access as judged by the treating physician

Keywords: pain analgesia ketamine intranasal emergency
manhattan vision screening and follow-up study (nyc-sight)

Conditions: Glaucoma; Vision Impairment and Blindness; Cataract; Diabetic Retinopathy; Eye Diseases

Summary: the investigators are conducting a 5-year prospective, 2:1 cluster-randomized controlled trial, funded by the centers for disease control (cdc), which provides vision screenings to underserved new york city residents living in affordable housing buildings in harlem and washington heights.

this study aims to increase engagement, detection and management of glaucoma, vision impairment, cataracts, and other eye diseases in vulnerable populations living in new york city. this study considers disparities by race, ethnicity, gender, geography, and socioeconomic status using innovative approaches such as patient navigators. individuals over the age of 40 living in new york city housing authority (nycha) housing buildings are eligible.

Eligibility criteria:
inclusion criteria: * individuals over age 40 * living independently in nycha housing building or attending dfta senior center * willing to answer covid-19 symptom questions * willing to consent for 2 vision screening visits at baseline and 12-month follow-up exclusion criteria: * self-reported terminal illness with life expectancy less than 1 year * inability to provide informed consent due to dementia or other reasons

Keywords: vision screening follow-up eye care vulnerable populations new york city
dwi mr-enterography without or with bowel cleansing to assess intestinal inflammatory activity in the follow-up of crohn's disease

Conditions: Crohn Disease; Bowel Cleansing; Apparent Diffusion Coefficient

Summary: since 2009, many studies tend to prove the effectiveness of diffusion-weighted mr-enterography in the assessment of inflammatory activity in ibd compared to standard mr-enterography, with the emergence of new radiological scores such as the clermont score. diffusion-weighted mri (dwi) is a faster technique and does not require the injection of gadoline contrast medium, which is a desirable in view of recent data on their long-term adverse effects (intracerebral deposits, nephrogenic systemic fibrosis). the advent of 3t mri, which provides a better signal, a better spatial resolution or the same examination quality in a shorter time, seems promising for the future of dwi. however, to date, there are still few studies carried out at 3t in this field or even few studies on the possibility of doing away with bowel cleansing, although this is one of the main demands of patients. all patients will undergo a simplified mr-enterography, which includes four sequences, without bowel cleansing or injection. on the same day, the standard mr-enterography will be performed as in clinical practice, after ingestion of the usual oral preparation. three reading sessions of the examination will be organized at intervals of at least one month by two radiologists specialized in digestive imaging, blinded to the clinical and


Eligibility criteria:
inclusion criteria: * any patient diagnosed with crohn's disease with bowel involvement for whom a mr-enterography was ordered as part of their follow-up * age ≥ 18 * subject's ability to understand and express opposition * affiliation to french social security system exclusion criteria: * any contraindication to mri * allergy to gadolinium chelates * claustrophobia * major obesity that does not allow the patient to enter the machine's tunnel (whose diameter is 70 cm) * pregnant woman * person under curators or guardianship

Keywords: crohn disease diffusion-weighted imaging mr-enterography bowel cleansing apparent diffusion coefficient